Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BMP4 | P12644 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3702394 | 0.98 | SMPD3 (0.37) | SMPD3AXLCDK2NPC1RAB9A | |
| SCHEMBL14699684 | 0.74 | SMPD3 (0.57) | SMPD3AXLCDK2BMP4IRAK4 | |
| SCHEMBL3122125 | 0.74 | SMPD3 (0.38) | SMPD3AXLCDK2BMP4LMNA | |
| SCHEMBL9935120 | 0.74 | SMPD3 (0.38) | SMPD3AXLCDK2BMP4NUDT1 | |
| SCHEMBL12970192 | 0.74 | CCNE1 (0.47) | CDK2BMP4IRAK4 | |
| Hydrochloric Acid SCHEMBL31619326 | 0.72 | SMPD3 (0.38) | SMPD3AXLCDK2NPC1RAB9A | |
| SCHEMBL2661228 | 0.72 | ALDH1A1 (0.49) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL20199464 | 0.72 | GSK3A (0.42) | RAB9ASMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL2380423 | 0.71 | IRAK4 (0.51) | KDM4EMAPTGSK3AHPGDHSD17B10 | |
| SCHEMBL179560 | 0.70 | PDE10A (0.38) | SMPD3AXLCDK2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| EP-3904355-B1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-09-05 | — | — | US | disclosed |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-09-05 | — | — | US | disclosed |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-09-05 | — | — | US | disclosed |
| EP-3808746-B1 | N-[3-[2-[8-[(1H-PYRAZOL-4-YL)AMINO]IMIDAZO[1,2-A]PYRAZIN-3-YL]ETHYNYL]PHENYL]-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SHENZHEN TARGETRX INC (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-3808746-B1 | N-[3-[2-[8-[(1H-PYRAZOL-4-YL)AMINO]IMIDAZO[1,2-A]PYRAZIN-3-YL]ETHYNYL]PHENYL]-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SHENZHEN TARGETRX INC (CN) | 2023-08-02 | — | — | EP | disclosed |
| CN-110272426-B | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20220098204-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3904355-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2021-11-03 | — | — | EP | disclosed |
| US-10065934-B2 | Substituted urea derivatives and pharmaceutical uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-04 | — | — | US | disclosed |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| WO-2016008433-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-01-21 | — | — | WO | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098204-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | BRAF, ALK, TYRO3 | SMPD3 4035/4885AXL 52/4885CDK2 238/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SMPD3 588/4885AXL 1068/4885CDK2 100/4885 |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | ALK, WEE1, WEE2 | SMPD3 3745/4885AXL 715/4885CDK2 99/4885 |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ULK2, ULK3, ULK1 | SMPD3 1873/4885AXL 677/4885CDK2 23/4885 |
| US-10065934-B2 | Substituted urea derivatives and pharmaceutical uses thereof | ULK2, ULK3, ULK1 | SMPD3 1873/4885AXL 677/4885CDK2 23/4885 |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | BRAF, ALK, TYRO3 | SMPD3 4035/4885AXL 52/4885CDK2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.